Zachary Bloomgarden, MD: the Onglyza launch
Diabetes expert Zachary Bloomgarden, MD of Mount Sinai medical Center in New York discusses the newly approved DPP4-inhibtor drug, Onglyza (saxagliptin) to compete with Januvia.
Diabetes, Endocrinology, Internal medicine, Mt Sinai NYC | apples49 | 
August 4, 2009 7:25 pm
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
